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ORIGINAL RESEARCH
The metabolic enzyme arginase-2 is a potential target for novel immune modulatory 
vaccines
Stine Emilie Weis-Bankea, Mie Linder Hübbea, Morten Orebo Holmström a, Mia Aaboe Jørgensena, 
Simone Kloch Bendtsena, Evelina Martinenaitea,b, Marco Carrettaa, Inge Marie Svane a, Niels Ødumc, 
Ayako Wakatsuki Pedersenb, Özcan Met a, Daniel Hargbøl Madsena, and Mads Hald Andersen a,b,c
aNational Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital Herlev, Copenhagen, Denmark; bIO 
Biotech ApS, Copenhagen, Denmark; cDepartment of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
ABSTRACT
One way that tumors evade immune destruction is through tumor and stromal cell expression of arginine- 
degrading enzyme arginase-2 (ARG2). Here we describe the existence of pro-inflammatory effector T-cells 
that recognize ARG2 and can directly target tumor and tumor-infiltrating cells. Using a library of 34 
peptides covering the entire ARG2 sequence, we examined reactivity toward these peptides in peripheral 
blood mononuclear cells from cancer patients and healthy individuals. Interferon-γ ELISPOT revealed 
frequent immune responses against several of the peptides, indicating that ARG2–specific self-reactive 
T-cells are natural components of the human T-cell repertoire. Based on this, the most immunogenic ARG2 
protein region was further characterized. By identifying conditions in the microenvironment that induce 
ARG2 expression in myeloid cells, we showed that ARG2-specific CD4T-cells isolated and expanded from 
a peripheral pool from a prostate cancer patient could recognize target cells in an ARG2-dependent 
manner. In the ‘cold’ in vivo tumor model Lewis lung carcinoma, we found that activation of ARG2-specific 
T-cells by vaccination significantly inhibited tumor growth. Immune-modulatory vaccines targeting ARG2 
thus are a candidate strategy for cancer immunotherapy.
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Introduction
Although the immune system can detect and destroy trans-
formed cells, most tumors evade this destruction through 
a wide range of escape mechanisms. The classical mechanisms 
include impairment of major histocompatibility complex 
(MHC)-mediated tumor antigen presentation and downregu-
lation of the costimulatory molecules B7.1 Of importance, 
a growing body of evidence indicates that tumors can promote 
an immunosuppressive microenvironment by recruiting or 
generating immunoregulatory cells, such as regulatory T-cells 
(Tregs), tolerogenic myeloid populations (especially tumor- 
associated macrophages, TAMs), myeloid-derived suppressor 
cells (MDSCs), and cancer-associated fibroblasts (CAFs). 
Among the immunosuppressive mechanisms that tumors 
employ is production of anti-inflammatory mediators, such 
as transforming growth factor-β (TGF β) and interleukin 
(IL)-10, exploitation of inhibitory molecules of the B7 family, 
such as PD-L1, and expression of amino acid–degrading 
enzymes such as arginase and indoleamine 2,3-dioxygen-
ase (IDO).
Arginase is a ubiquitous enzyme that catalyzes the degrada-
tion of L-arginine to L-ornithine and urea. There are two iso-
forms of arginase in mammals: arginase-1 (ARG1), a cytosolic 
enzyme predominantly present in the liver, and arginase-2 
(ARG2), which is expressed in the mitochondrial matrix .2 By 
regulating the availability of L-arginine and L-ornithine, argi-
nase is important in normal and cancer cells. Its expression in 
the tumor microenvironment dampens cancer-specific 
immune responses through local and systemic suppression of 
T-cell proliferation, inhibition of T-cell activation, promotion 
of T-cell anergy and apoptosis, and macrophage reprogram-
ming that promotes immunosuppressive phenotypes.3–5
In general, most studies of arginase have focused on ARG1, 
whereas ARG2 has received less attention to its potential role in 
cancer. Although studies have linked high arginase activity 
with various cancers and serum arginase activity with disease 
progression, these studies did not discriminate between ARG1 
and ARG2. One group did show in 2005 that ARG2 is highly 
expressed in human prostate cancer,4 and the enzyme was 
further described as suppressing tumor-infiltrating lympho-
cytes. Androgens enhance ARG2 expression, and androgen- 
depletion therapy that decreases ARG2 activity can boost 
immune responses by increasing T-cell activation and inter-
feron (IFN)γ secretion in vivo.6 ARG2 also distinguishes malig-
nant follicular thyroid carcinoma from benign follicular 
thyroid adenoma.7,8 Likewise, in head and neck squamous 
cell carcinomas, ARG2 expression has been correlated with 
a poor prognosis .9 Its expression in breast cancer cells has 
additionally been reported,10 and its levels are significantly 
higher in breast cancer tissue and peripheral blood compared 
to healthy donors.11 ARG2 activity is also described as being 
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enhanced in gastric cancer when compared with healthy gastric 
tissue,12 and the enzyme is released in vitro by gastric cancer 
cell lines and in the serum of patients with gastric cancer.9,13 In 
addition to solid tumors, enhanced ARG2 expression has been 
described in acute myeloid leukemia (AML). Of interest, cir-
culating AML blasts are phenotypically similar to MDSCs but 
express and release ARG2 (rather than ARG1) in peripheral 
blood, suppressing T-cell activity.14,15 These results collectively 
suggest that ARG2 is a promising target for boosting tumor- 
specific immune responses and addressing the general state of 
immunosuppression and pancytopenia seen with AML.
Recently, CAFs have emerged as abundant and crucial 
components of the tumor mesenchyme. CAFs are involved in 
modulation of immune system factors, with recently revealed 
roles in immune evasion and poor responses to cancer 
immunotherapy.16 Of interest, Ino et al. evaluated pancreatic 
ductal carcinoma tissues from 200 cases and detected ARG2 
protein expression in CAFs, especially those located within and 
around necrotic areas of the tumor.9 The presence of ARG2- 
expressing CAFs correlated with poor overall and disease-free 
survival, emphasizing their key role in immune regulation of 
the tumor microenvironment. ARG2 also is involved in obe-
sity-associated pancreatic cancer.11
Pro-inflammatory T-cells that specifically target immune- 
suppressive cells are intrinsically present in the periphery and 
counteract a range of regulatory immune-feedback signals 
(reviewed in17). These T-cells (coined anti-regulatory T-cells 
or anti-Tregs18 because of their role in targeting regulatory 
immune mechanisms) recognize human leukocyte antigen 
(HLA)-restricted epitopes, generated from degraded intracel-
lular self-antigens derived from immune inhibitory proteins, 
such as ARG1.19–21 We previously described the existence of 
ARG1-specific T-cells and demonstrated that they recognize 
and react against dendritic cells (DCs) and B cells expressing 
ARG1,19 and that these preexisting T-cell responses against 
ARG1 are part of the T-cell memory repertoire.20 A phase 
I vaccination trial with ARG1 peptides was recently initiated 
at our institution (NCT03689192).22 In the current study, we 
examined if ARG2 likewise is a target for specific effector 
T-cells and if these cells can react toward cells expressing 
ARG2.
Results
Spontaneous immune responses toward ARG2
To determine whether antigens derived from ARG2 can be 
targeted by specific T-cells, we screened for ARG2 peptide 
epitopes that elicited an immune response in peripheral 
blood mononuclear cells (PBMCs) from healthy donors. For 
this purpose, we generated a library of 34 peptides covering the 
entire ARG2 protein sequence. All peptides were 20-mers, and 
each one overlapped with the first 10 amino acids of the 
subsequent sequence (supplementary table 1). We divided the 
peptides into 11 pools of 3–4 adjacent peptides (supplementary 
table 1) and used PBMCs from six healthy donors (HDs) to 
screen for immune responses to the library peptides. Briefly, 
PBMCs were stimulated once with each peptide pool before 
being examined in IFNγ ELISPOT assays with stimulation of 
each peptide individually. We observed immune responses 
toward several different ARG2 peptides with ARG2-1, ARG2- 
5, ARG2-8, ARG2-13, ARG2-18, ARG2-20, ARG2-21, and 
ARG2-22 showing the highest and most abundant responses 
(Figure 1a). We then validated the immune responses toward 
these eight peptides in IFNγ ELISPOT assays. PBMCs from the 
same HDs as above were stimulated with each peptide indivi-
dually. In Figure 1b the immune responses against the peptides 
that are either covering the signal peptide region of ARG2 or 
the peptides located in the region corresponding to the most 
immunogenic region of the ARG1 sequence. Although we 
could detect immune responses in this region of ARG2, the 
most immunogenic peptide was ARG2-1(supplementary fig-
ure 1). Of interest, ARG2-1 is a part of the transit sequence 
(aa1–22) of ARG2. Signal peptide sequences represent an 
interesting type of epitopes that largely do not depend on 
proteasomal degradation or TAP (Transporter associated 
with antigen processing protein) for their processing and pre-
sentation in the context of HLA molecules.23–25 Furthermore, 
this part of ARG2 has very limited overlap with the corre-
sponding sequence of ARG1 (Figure 1c).
We then used ARG2-1 to screen for ARG2 immune 
responses in samples from 33 HDs and 19 cancer patients 
with metastatic solid tumor (11 melanoma, 1 breast and 7 
prostate cancer patients) by IFNγ ELISPOT assay. Samples 
from both groups showed strong and frequent responses 
(Figure 2a), with significant responses in around 75% of the 
screened donors. Because ARG2 is reported to play an impor-
tant role in the immunosuppressive microenvironment 
observed in patients with AML,14,15 we used IFNγ ELISPOT 
to assess for the presence of ARG2-specific T-cells among 
PBMCs from nine patients diagnosed with AML. Blood collec-
tion and subsequent PBMC isolation were performed indepen-
dently of treatment status, thus the patients represent very 
different disease and treatment stages. We observed 
a significant response in three of the nine patients 
(Figure 2a), suggesting that ARG2-specific T-cells indeed can 
be present in patients with AML. In supplementary table 2 the 
clinical characteristics of the included AML patients are 
depicted. Intracellular cytokine staining for IFNγ and tumor 
necrosis factor (TNF)α production in HDs and cancer patients 
with solid tumors primarily showed CD4+responses to ARG2- 
1 (Figure 2b).
Characterization of long ARG2 peptide epitopes
We have previously shown that a longer (38-mer) ARG1 pep-
tide is superior at stimulating ARG1-specific T-cells compared 
to 20- and 30mer ARG1 peptides from the same region.20 Here 
we sought to identify an optimal, immunogenic ARG2-derived 
peptide that broadly stimulates ARG2-specific T-cells in sub-
jects with different tissue types. For this purpose, we designed 
a longer ARG2 peptide epitope spanning larger parts of the 
sequence around ARG2-1, based on HLA prediction algo-
rithms (available at www.syfpeithi.de and cbs.dtu.dk). To test 
whether these long ARG2 peptides (Figure 3a and supplemen-
tary table 1) could be used to identify ARG2 responses, PBMCs 
from six HDs were stimulated once with each of the three long 
peptides. Subsequently, PBMCs were used to screen for 
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immune responses in IFNγ ELISPOT. As shown in Figure 3b, 
immune responses against all three long peptides were identi-
fied; however, the 33-mer A2L2 gave the strongest and most 
frequent immune responses of the three long peptides in the 
examined donors. Because ARG2-1 is contained within A2L2, 
we examined if this longer peptide more effectively stimulated 
ARG2-specific T-cells, using IFNγ ELISPOT assay of samples 
from six HDs, stimulated with either ARG2-1 or A2L2 once. In 
five of six donors, A2L2 immune responses were higher than 
ARG2-1 responses (Figure 3c), although not reaching signifi-
cance (p = .06), suggesting that both peptides elicit frequent 
immune responses.
To characterize the immunogenicity of A2L2, we screened 
PBMCs from 30 HDs and 18 patients with cancer (14 mela-
noma, 3 prostate, 1 breast) by IFNγ ELISPOT assay. We 
observed strong and frequent responses in both HDs and 
patients with cancer (Figure 3d). Intracellular cytokine staining 
for IFNγ and TNFα production showed only CD4+ responses 
to A2L2 stimulation (Figure 3e), similar to our observations for 
ARG2-1. The immune responses toward A2L2 were on average 
higher compared to ARG2-1 responses in the same donor, 
although not significantly so (p = .7) (figure 3f).
Characterization of ARG2-specific T-cells
To further characterize the immune response toward ARG2, we 
generated an ARG2-specific CD4 + T-cell culture. To do so, we 
used ARG2-1 peptide–loaded autologous DCs to repeatedly 
stimulate PBMCs isolated from a patient with prostate cancer, 
followed by enrichment and rapid expansion of specific cells 
(supplementary figure 2a). The T-cell culture was highly specific 
toward both ARG2-1 and A2L2, based on intracellular cytokine 
staining for TNFα and IFNγ (ARG2-1, Figure 4a) and IFNγ 
ELISPOT results (Figure 4b). Furthermore, we found that IFNy 
production from the ARG2-specific T-cell culture stimulated 
with peptide were inhibited by the addition of HLA-DR block-
ers, but not HLA-DP or HLA-DQ blockers in IFNy ELISPOT 
(Figure 4c). To assess the specificity of the ARG2-specific T-cell 
Figure 1. Multiple ARG2 peptides are recognized by PBMCs from healthy donors. (a) IFNγ ELISPOT screening of responses against overlapping 20-mer ARG2 peptides 
from six healthy donors. 4–4.5 × 105 cells were plated per well, and peptide and control stimulation were performed in duplicate or triplicate. Specific spot counts 
(peptide-specific IFNγ-secreting cells) are given as the difference in number of IFNγ spots between averages of the wells stimulated with peptide and control wells. (b) 
IFNγ ELISPOT responses from the screening toward the peptides here covering the signal peptide region of ARG2 (left; ARG2-0, ARG2-1, ARG2-2) or the peptides located 
in the region corresponding to the most immunogenic region of the ARG1 sequence (right; ARG2-17, ARG2-18, ARG2-19, ARG2-20 og ARG2-21). (c) Alignment of ARG1 
and ARG2 amino acid sequence around the ARG2-1 sequence. The ARG2-1 sequence is highlighted and marked in red.
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culture we looked at the ability of the ARG2-specific T-cell 
culture to recognize and react against cells with intracellular 
expression of ARG2. To this end, we transfected autologous 
DCs with mRNA encoding ARG2 fused to the DC-LAMP signal 
sequence, which targets a protein toward the lysosomal com-
partment and thus directs the protein toward HLA class II 
presentation.26 We observed higher reactivity against ARG2 
mRNA transfected DCs compared to mock transfected DCs 
(Figure 4d). FACS analysis of transfected cells showed >90% 
transfection efficiency (supplementary figure 2b) and mRNA 
analysis of mock and mRNA transfected DC showed a large 
increase in ARG2 expression 24hrs after transfection (supple-
mentary figure 2c).
Having shown reactivity toward ARG2-producing immune 
cells we next set out to investigate the ability of the ARG2- 
specific T-cell culture to recognize and react against different 
cancer cells using IFNy ELISPOT assays. HLA sequencing 
analysis of the donor for the specific T-cell culture allowed us 
to choose three HLA-matched (HLA-DR01:01) AML cell lines 
with low endogenous ARG2 expression (OCI-AML2, THP-1 
and MONO-MAC-1, supplementary figure 3) and pulse with 
ARG2-1 peptide to subsequently use as target T-cells for IFNy 
ELISPOT. Set2, another AML cell line with high endogenous 
ARG2 expression (supplementary figure 3) but HLA-mismatch 
with the ARG2-specific T-cell culture, was included as 
a negative control. OCI-AML2, THP-1 and MONO-MAC-1 
pulsed with ARG2-1 peptide were effectively recognized by the 
ARG2-specific T-cells (Figure 5a), whereas Set2 was not. The 
HLA-DR restriction of the ARG2-specific T-cells was con-
firmed by the addition of two different HLA-DR specific anti-
bodies, since addition of both HLA-DR blockers abrogated the 
recognition of ARG2-1 pulsed THP-1 cells (Figure 5b).
The THP-1 cell line is a monocytic cell line derived from 
peripheral blood of a patient with AML.27 THP-1 cells are 
reported to have maintained some plasticity, with their function 
depending on the presence of specific cytokines in their sur-
roundings. IL-4 and IL-13 are reported to be the main inducers 
of ARG1,3 but their effect on ARG2 is not well known. 
Moreover, THP-1 cells are reported to acquire DC-like charac-
teristics upon 48 hrs of stimulation with a cytokine cocktail of 
IL-4, GM-CSF, and TFNα.28 We therefore examined if stimula-
tion of THP-1 cells with IL-4, IL-13, or the cytokine cocktail 
would increase ARG2 expression in THP-1 cells. We found 
a more than 2-fold induction of ARG2 expression upon stimula-
tion with the cytokine cocktail, whereas IL-4 and IL-13 did not 
have much effect on ARG2 expression levels (Figure 5c). We 
then turned to investigate if the increase in ARG2 expression 
after cytokine cocktail stimulation could elicit an immune 
response from ARG2-specific T-cells. Indeed, we found that 
the cytokine cocktail led to recognition of the stimulated THP- 
1 cells in IFNy ELISPOT (Figure 5d) and production of TNFα 
and IFNy detected by intracellular cytokine staining (Figure 5e). 
Only ARG2 expression increased after treatment of the THP-1 
cells with the cytokines, whereas ARG1 expression remained 
unchanged (figure 5f). The response toward cytokine stimulated 
THP-1 cells could be blocked by HLA-DR specific antibodies 
Figure 2. ARG2-1 is widely recognized by PBMCs from both healthy donors and cancer patients with solid tumors or AML. (a) IFNγ ELISPOT responses against ARG2-1 
peptide in PBMCs from healthy donors (n = 33), cancer patients with solid tumors (n = 19), or cancer patients with AML (n = 19). 3–4 × 105 cells were plated per well. 
Peptide and control stimulations were performed in triplicate. Each spot represents one donor and is the number of peptide-specific IFNγ-secreting cells (the difference 
between the average of wells stimulated with peptide and control wells). (b) Representative intracellular cytokine staining for IFNγ and TFNα production in samples 
from healthy donors (HD49 and HD50) and a cancer patient (AA27) with solid tumors stimulated with ARG2-1 or non-stimulated control.
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Figure 3. The long ARG2 peptide A2L2 elicits strong and frequent CD4 + T-cell responses in samples from healthy donors and cancer patients. (a) Aligned peptide 
sequences of the library peptides ARG2-0, ARG2-1, and ARG2-2 and the long peptides ARG2-Long1 (A2L1), ARG2-Long2 (A2L2), and ARG2-Long3 (A2L3). The signal 
sequence of ARG2 is shown for comparison. (b) IFNγ ELISPOT responses against the long peptides A2L1, A2L2, and A2L3 in PBMCs from six healthy donors. 4 × 105 cells 
were plated per well, and peptide and control stimulation were performed in triplicate. Specific spot counts (peptide-specific IFNγ-secreting cells) are given as the 
difference in number of IFNγ spots between averages of the wells stimulated with peptide and control wells. Responses against peptide were too numerous to count 
(TNTC) in 3 settings and set to be >750 spots. (c) IFNγ ELISPOT responses to A2L2 and ARG2-1 in PBMCs from 6 healthy donors. 4 × 105 cells were plate per well, and 
peptide and control stimulation were performed in triplicate. Specific spot counts (peptide-specific IFNγ-secreting cells) are given as the difference in number of IFNγ 
spots between averages of the wells stimulated with peptide and control wells. * p ≤ 0.05 or ** p ≤ 0.01 according to the distribution free resampling rule. (d) IFNγ 
ELISPOT responses against A2L2 peptide in PBMCs from healthy donors (n = 30) and cancer patients with solid tumors (n = 18). 3–4 × 105 cells were plated per well. 
Peptide and control stimulations were performed in triplicate. Each spot represents one donor and is the number of peptide-specific IFNγ-secreting cells (the difference 
between the average of wells stimulated with peptide and control wells). (e) Representative intracellular cytokine staining for IFNγ and TFNα production in samples from 
healthy donors (HD48 and HD53) and a cancer patient (AA27) with solid tumors stimulated with A2L2 or non-stimulated control. (f) FNγ ELISPOT responses to ARG2-1 
and A2L2 in PBMCs from healthy donors (n = 26) and cancer patients with solid tumors (n = 11) for comparison of the magnitude of responses to the two peptides. 
4 × 105 cells were plated per well, and peptide and control stimulation were performed in triplicate. Specific spot counts (peptide-specific IFNγ-secreting cells) are given 
as the difference in number of IFNγ spots between averages of the wells stimulated with peptide and control wells. ns: p = .7038.
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(Figure 5g). Of note, the cytokine cocktail-stimulated THP-1 
cells changed morphology compared to unstimulated cells with 
more colony-formation, small protrusions, and an acquired 
adherence (supplementary figure 4a). Importantly, the cytokine 
cocktail did not upregulate HLA-DR expression (supplementary 
figure 5a). In contrast, treatment of THP-1 cells with IFNy 
increased HLA-DR expression on the cell surface (supplemen-
tary figure 5a), but not ARG2 expression (Figure 5h), and IFNy 
stimulated THP-1 cells were not recognized by ARG2-specific 
T-cells in IFNy ELISPOT assay (Figure 5i).
MONO-MAC-1 is an AML cell line that, like THP-1 cells, 
can differentiate in response to or be affected by cytokine 
stimulation.29 Similar to our observations for THP-1 cells, the 
cytokine cocktail could increase ARG2 expression in MONO- 
MAC-1 cells (Figure 6a). Stimulation of MONO-MAC-1 cells 
with the cytokine cocktail did not increase HLA-DR expression 
Figure 4. ARG2-specific T-cells recognize ARG2-expressing dendritic cells. (a) ARG2-specific T-cells were expanded from samples from a patient with prostate cancer. The 
specificity of the T-cell culture was assessed by intracellular cytokine staining for TFNα and IFNγ production in peptide-stimulated cells and a non-stimulated control. 
Left: Dot plot for ARG2-1 peptide-stimulated and non-stimulated (control) cells. Right: % CD4 T-cells producing IFNγ, TFNα, or both (DP: double positive) in response to 
control stimulation (no peptide), ARG2-1 peptide stimulation, or A2L2 peptide stimulation. (b) Specificity of the ARG2-specific T-cells assessed by ELISPOT responses to 
control stimulation (no peptide), ARG2-1 peptide, or A2L2 peptide. 4 × 104 cells were plated per well. TNTC, too numerous to count (more than 500 spots). (c) he HLA- 
restriction of ARG2-specific T-cells were examined. IFNγ ELISPOT response of the ARG2-specific T-cells toward ARG2-1 peptide in the presence of different class II 
blockers. (d) IFNγ ELISPOT response by the ARG2-specific T-cells to autologous dendritic cells transfected with irrelevant control mRNA (mock mRNA) or ARG2 mRNA. 
Effector-to-target ratio 5:1 with 5 × 104 effector cells plated per well. * p ≤ 0.05 or ** p ≤ 0.01 according to the distribution free resampling rule.
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Figure 5. ARG2-specific T-cells recognize ARG2-expressing malignant myeloid cells. (a) To identify HLA-matched malignant T-cells, the ARG2-specific T-cells were 
examined in IFNγ ELISPOT response toward different relevant cancer cell lines pre-pulsed with ARG2-1 peptide. The same cancer cell lines without peptide stimulation 
were examined as control. Effector-to-target ratio 1:1 with 1 × 104 effector cells plated per well. * p ≤ 0.05 or ** p ≤ 0.01 according to the distribution free resampling 
rule. TNTC, too numerous to count (>500). (b) FNγ ELISPOT response of the ARG2-specific T-cells toward THP-1 cells pulsed with ARG2-1 peptide and class II blockers. (c) 
ARG2 expression in THP-1 evaluated by RT-qPCR following 48-h incubation of THP-1 cells with different cytokines. Data are represented as fold change vs unstimulated 
THP-1 cells; mean+SD, n = 4. (d) FNγ ELISPOT response of the ARG2-specific T-cells toward THP-1 cells stimulated with the cytokine cocktail. Effector-to-target ratio 5:1 
with 1.5 × 105 effector cells plated per well. ** p ≤ 0.01 and ns = not significant according to the distribution free resampling rule. (e) Intracellular staining of TFNα and 
IFNγ production from CD4 + T-cells in the ARG2-specific T-cell culture when incubated with unstimulated THP-1 cells or THP-1 cells pre-stimulated with cytokine cocktail 
for 48 h. Effector-to-target ratio 2:1 with 500,000 effector cells used per condition. (f) RG1 and ARG2 expression in THP-1 cells evaluated by RT-qPCR following 48-h 
incubation with cytokine cocktail. Unstimulated THP-1 cells served as control. Data are represented as relative expression to the housekeeping gene ACTB; mean+SD, 
n = 4. (g) IFNγ ELISPOT response of the ARG2-specific T-cells toward THP-1 cells stimulated with the cytokine cocktail (THP-1 + cyto) and the class II blocker, aHLA-DR. 
Effector-to-target ratio 5:1 with 1.5 × 105 effector cells plated per well. ** p ≤ 0.01 and ns = not significant according to the distribution free resampling rule. (h) ARG2 
expression in THP-1 cells evaluated by RT-qPCR following 48-h stimulation with cytokine cocktail (Th2 cocktail) or IFNγ. Unstimulated THP-1 cells were included as 
control. Data are represented as relative expression to the housekeeping gene RPO; mean+SD, n = 4. (i) IFNγ ELISPOT response of the ARG2-specific T-cells toward THP-1 
cells pre-stimulated with the cytokine cocktail (THP-1 + cytokines) or IFNγ (THP-1 + IFNγ). Effector-to-target ratio 2.5:1 with 5 × 104 effector cells plated per well. ** 
p ≤ 0.01 and ns = not significant according to the distribution free resampling rule.
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compared to unstimulated cells (supplementary Figure 5b). 
Furthermore, MONO-MAC-1 cells stimulated with IFNγ did 
not upregulate ARG2 expression (Figure 6b), and only cytokine 
cocktail-treated MONO-MAC-1 cells were recognized by the 
ARG2-specific T-cells in the IFNγ ELISPOT (Figure 6c). 
MONO-MAC-1 stimulated with the cytokine cocktail also 
changed morphology in ways similar to our observations 
with THP-1 cells (supplementary figure 4b).
To further test the notion of ARG2 expression–dependent 
T-cell recognition, we transfected THP-1 cells with ARG2 
mRNA using the ARG2-DC-LAMP construct. The DC-LAMP 
sequence is reported to be specific for mature DCs, 26 but THP- 
1 cells can be differentiated into DC-like cells, so the construct 
can be applicable for transfection of THP-1 cells. We observed 
that the ARG2-specific T-cell culture reacted toward THP-1 
cells transfected with ARG2-DC-LAMP mRNA (Figure 7a). 
The reactivity was significantly higher toward cells transfected 
with ARG2-DC-LAMP mRNA compared to those only mock- 
transfected (Figure 7a), emphasizing the specificity of the 
ARG2-specific T-cells. Furthermore, with 48 hours of cytokine 
cocktail stimulation before transfection, the immune response 
increased compared to cells that were only mRNA-transfected 
or only cytokine-cocktail-stimulated (Figure 7a). Intracellular 
cytokine staining for TNFα and IFNγ production showed 
a similar trend (Figure 7b). We assessed the electroporation 
efficiency at 24 hours post transfection by FACS analysis of 
green fluorescent protein (GFP)-expressing cells and showed 
efficient transfection (>99% GFP+ cells) (supplementary figure 
6a). In line with this, we observed a large fold increase in ARG2 
and ARG1 expression compared to mock-transfected cells at 
24 hours post transfection with ARG2-DC-LAMP mRNA or 
ARG1-DC-LAMP mRNA, respectively (supplementary figure 
6b and 6 c). ARG2 expression levels in mRNA-transfected 
THP-1 cells were high compared to endogenous ARG2 expres-
sion levels in Set2 cells (supplementary figure 6d).
Next, we used small-interfering (si)RNA-mediated 
knockdown of ARG2 to further confirm that T-cell recog-
nition and activation was dependent on ARG2 expression. 
Transfection of THP-1 cells with a pool of three ARG2- 
specific siRNAs led to efficient ARG2 knockdown 
(Figure 7c). We assessed TNFα and IFNγ production by 
intracellular cytokine staining at 48 hours after transfec-
tion with siRNAs and cytokine-cocktail stimulation. Both 
TNFα and IFNγ production decreased from ARG2-specific 
T-cells reacting toward siRNA+cytokine cells compared to 
mock+cytokine cells, even if production was not comple-
tely abrogated (Figure 7d). RT-qPCR of ARG2 expression 
in the cells also showed ARG2 knockdown in siRNA 
Figure 6. ARG2-specific T-cells recognize several ARG2-expressing malignant myeloid cells. (a) RG2 expression in MONO-MAC-1 (MM1) cells evaluated by RT-qPCR 
following a 48-h incubation with cytokine cocktail. Data are represented as fold change vs unstimulated MM1 cells; mean+SD, n = 4. (b) ARG2 expression in MM1 cells 
evaluated by RT-qPCR following a 48-h incubation with cytokine cocktail or IFNγ. Data are represented as fold change vs unstimulated MM1 cells; mean+SD, n = 4. (c) 
IFNγ ELISPOT response of the ARG2-specific T-cells toward MM1 cells pre-stimulated with the cytokine cocktail (MM1 + cytokine cocktail) or IFNγ (MM1 + IFNγ). Effector- 
to-target ratio 2.5:1 with 5 × 104 effector cells plated per well. ** p ≤ 0.01 and n = not significant according to the distribution free resampling rule.
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+cytokine cells, but ARG2 expression levels were slightly 
higher than the levels obtained with only siRNA knock-
down (Figure 7e).
ARG2 vaccination in vivo
To examine a potential functional effect of ARG2-specific 
T-cells in vivo, we went on to identify relevant murine ARG2 
peptide epitopes. We screened the murine ARG2 protein 
sequence for possible MHC binding peptide epitopes using 
the SYFPEITHI and NetMHC epitope prediction algorithms 
(available at www.syfpeithi.de and cbs.dtu.dk, respectively). Six 
high scoring peptide epitopes spread across ARG2 protein 
(supplementary table 3) were selected for evaluation. To this 
end, we screened for immune responses in C57BL/6 mice by s. 
c. vaccination of mice in a peptide-montanide emulsion. Three 
mice per group were vaccinated with each of the 6 candidate 
peptides, and 7 days later mice were sacrificed, spleens were 
retrieved, and PBMCs were isolated and analyzed in an ex vivo 
mIFNy ELISPOT assay. We observed strong immune 
responses in all 3 mice vaccinated with mARG2(188–197) 
(denoted P4) (Figure 8a). This was subsequently confirmed in 
a similar experiment with a larger number of mice per group 
(Figure 8b).
To identify the most relevant tumor model for evaluating 
the therapeutic effect of ARG2 vaccination, we evaluated ARG2 
expression in a panel of different engrafted tumors of C57BL/6 
origin. Of the six tumor cells examined, Lewis lung carcinoma 
(LL/2) tumor cells were found to express consistently high 
levels of ARG2 (Figure 8c) and were therefore chosen for 
evaluation of ARG2 vaccination in vivo. Challenge of C57BL/ 
6 mice with LL/2 tumor cells followed by ARG2 (P4) vaccina-
tion on day 0 and day 7 (Figure 8d) was found to cause 
a significant tumor growth delay compared to untreated con-
trol mice (Figure 8e). At all evaluated time points, the tumors 
from ARG2 vaccinated mice were significantly smaller than the 
tumors from the untreated control mice (figure 8f). Mice were 
sacrificed at day 10 after tumor inoculation due to tumor 
Figure 7. The recognition of ARG2-expressing cells by ARG2-specific T-cells dependent on the level of ARG2 expression in addition to the antigen-processing apparatus 
of the target T-cells. (a) IFNγ ELISPOT response of the ARG2-specific T-cells toward THP-1 cells unstimulated or pre-stimulated with the cytokine cocktail and mock 
transfected or transfected with ARG1 or ARG2 mRNA. Effector-to-target ratio 2.5:1 with 5 × 104 effector cells plated per well. ** p ≤ 0.01 and ns = not significant 
according to the distribution free resampling rule. (b) Intracellular staining of TFNα and IFNγ production from CD4 + T-cells in the ARG2-specific T-cell culture when 
incubated with unstimulated THP-1 cells or THP-1 cells pre-stimulated with cytokine cocktail followed by either mock (mock) or ARG2 mRNA (mRNA) transfection. 
Effector-to-target ratio 2:1 with 500,000 effector cells used per condition. DP: Double Positive. (c) ARG2 expression in THP-1 cells evaluated by RT-qPCR at 48 h post 
transfection with ARG2-specific siRNA. Data are represented as fold change vs mock-transfected THP-1 cells; mean+SD, n = 4. (d) Intracellular staining of TFNα and IFNγ 
production from CD4 + T-cells in the ARG2-specific T-cell culture when incubated with mock- or siRNA-transfected cells kept under unstimulated or cytokine cocktail 
stimulated conditions for 48 h prior to setup. Effector-to-target ratio 2:1 with 500,000 effector cells used per condition. (e) ARG2 expression in THP-1 cells evaluated by 
RT-qPCR at 48 h post transfection with ARG2-specific siRNA followed by cytokine cocktail stimulation. Data are represented as fold change vs unstimulated mock- 
transfected THP-1 cells; mean+SD, n = 4.
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Figure 8. ARG2 vaccination results on LL/2 tumor growth delay. (a) Murine IFNy ELISPOT screening of PBMCs from the spleens of C57BL/6 mice vaccinated with one of 
six different predicted ARG2 epitopes. 8*10^5 cells were plated pr. well and peptide and control stimulation were performed in triplicates. Specific spot counts (peptide- 
specific IFNy secreting cells) are given as the difference in number of IFNy spots between averages of the wells stimulated with peptide and control wells. (b) Murine 
IFNy ELISPOT of PBMCs from the spleen of C57BL/6 mice vaccinated with ARG2 peptide P4 (M1-M5) or a control vaccination (Ctrl1-4). 8*10^5 cells were plated pr. well 
and peptide and control stimulation were performed in triplicates. Specific spot counts (peptide-specific IFNy secreting cells) are given as the difference in number of 
IFNy spots between averages of the wells stimulated with peptide and control wells.(c) ARG2 expression in engrafted tumors of different origin in C57BL/6 background. 
3 engrafted tumors were evaluated pr. tumor type. Data are represented as relative expression to the housekeeping gene Hprt1, mean+SD, n = 3. (d) Treatment 
schedule for ARG2 (P4) vaccination in Lewis lung carcinoma (LL/2) challenged mice. On day 0, 0.5*10^6 LL/2 tumor cells were injected subcutaneously in the right flank 
of female C57BL/6 mice. Hereafter, mice were left untreated or received either control vaccination or ARG2 vaccination on day 0 and 7. (e) Average growth of LL/2 
tumors in untreated or ARG2 (P4) vaccinated mice (n = 15 for each group). Female C57BL/6 mice were inoculated with LL/2 cells and were left untreated or received 
ARG2 (P4) vaccination on day 0 and 7, as indicated in (d). Error bars indicate the standard error of the mean (SEM). * = p = .013 (Two-way ANOVA with Bonferroni 
correction). (f) Individual tumor sizes from the treatment groups described in (e). Error bars indicate the standard deviation (SD). *** = p ≤ 0.001 (Two-tailed Student 
t-test). (g) Average tumor growth of LL/2 tumors in control vaccinated or ARG2 (P4) vaccinated mice (n = 20 for each group). Female C57BL/6 mice were inoculated with 
LL/2 cells and received either control vaccination or ARG2 (P4) vaccination on day 0 and 7, as indicated in (d). Error bars indicate the standard error of the mean (SEM). 
**** = p ≤ 0.0001 (Two-way ANOVA with Bonferroni correction). (h) Individual tumor sizes from the treatment groups described in (g). Error bars indicate the standard 
deviation (SD). **** = p ≤ 0.0001 (Two-tailed Student t-test).
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ulceration. To confirm that the observed tumor growth delay 
was attributed to the effect of vaccine-primed ARG2-specific 
T cells and not merely due to unspecific immune activation 
from the adjuvant, we decided to compare the LL/2 tumor 
growth of ARG2 (P4) vaccinated to control vaccinated mice. 
As previously described, mice were challenged with LL/2 
tumor cells and vaccinated with ARG2 (P4) peptide on day 0 
and 7. Control vaccinated mice similarly received two vaccina-
tions consisting of a Montanide:H20 emulsion (Figure 8d). 
Encouragingly, the ARG2 (P4) vaccination resulted in 
a significant tumor growth delay compared to the control 
vaccinated group (Figure 8g), indicating a therapeutic effect 
of ARG2-primed T cells. At all evaluated time points, the 
tumors were found to be significantly smaller in the ARG2 
vaccinated group compared to the control vaccinated group 
(Figure 8h). Mice were sacrificed on day 12 after inoculation 
due to ulceration of tumors.
Discussion
Here we describe ARG2-specific effector T-cells that offer 
a potential, novel means of targeting ARG2-expressing immu-
nosuppressive cells. By screening a peptide library covering the 
entire ARG2 sequence, we first identified peripheral ARG2- 
specific T-cells that are naturally present in the peripheral 
blood from patients with cancer and from HDs. Of interest, 
ARG2 contains multiple epitopes that peripheral T cells recog-
nized amongst many subjects. The frequent T-cell responses 
against ARG2 emphasize the high immunogenicity of ARG2 
and support the likelihood of boosting an ARG2-specific 
immune response in ARG2-expressing cancers, e.g., prostate 
cancer or AML. In AML we detected strong responses in 3 out 
of 9 examined patients. Interestingly these three patients with the 
strong ARG2-responses had de novo AML, whereas none of the 
patients who had progressed to AML from a more indolent 
disease (MPN or MPN) had an ARG2-response. This could 
suggest an exhaustion of ARG2-specific T-cells in the pre-AML 
phase in these patients that may subsequently have led to an 
escape. Furthermore, high frequency of ARG2-specific responses 
in healthy individuals suggest that these T-cells are a natural part 
of the immune system and may play an important role for 
immune homeostasis .17 Naturally, this also suggests that the 
spontaneous T-cell response toward ARG2 is not necessarily 
directly linked to the malignant disease. However, our demon-
stration that ARG2 specific CD4 + T-cells are able to directly 
recognize and react to malignant myeloid cells in an ARG2- 
dependent manner, suggest that ARG2 specific T-cells will be 
able to react against both malignant and nonmalignant T-cells in 
an ARG2-expressing TME.
In general, tumors are now divided into different categories 
depending on the immune infiltration, as follows: (i) a scant 
immune infiltrate (‘cold’ tumors); (ii) an immune infiltrate 
precluded from contacting malignant T-cells ‘excluded’ 
tumors); and (iii) an abundant tumor infiltrate (‘hot’ tumors), 
held in check by robust immunosuppressive mechanisms.30 An 
important therapeutic strategy involves using clinical combi-
nations that convert ‘cold’ and ‘excluded’ tumors into ‘hot’ 
tumors, because the latter are generally associated with 
improved disease outcomes with immunotherapy, especially 
checkpoint blockade. An important characteristic of arginase 
is its expression in the ‘excluded’ tumor types because of 
arginase-expressing immune-suppressive cells in these tumors. 
ARG1 is upregulated in M2-like macrophages in response to 
cytokines such as IL-4 and IL-13, in addition to IL-10 and 
transforming growth factor-β.31 In contrast, the regulation of 
ARG2 has been less well-characterized, but its expression can 
be induced in murine macrophages by Toll-like receptor 
ligands such as lipopolysaccharide and oligodeoxynucleotides 
containing high amounts of unmethylated cytosine guanine 
motifs.32 Furthermore, IL1β and TNFα induce ARG2 in neu-
roblastoma cells.33 Here we show that a mixture of cytokines 
(i.e., IL4, GM-CSF, and TNF-α) induces ARG2 in malignant 
myeloid cells. Thus, ARG2 seems to be induced by environ-
ments of both excluded tumors and the more ‘intermediate’ to 
‘hot’ tumors. Our data shows that Arg-2-specific self-reactive 
T cells are a naturally occurring part of T-cell repertoire of the 
human immune system even in healthy donors. Interestingly, 
the T-cell responses against the individual peptides in the 
periphery varied. This may of cause simply reflect different 
HLA-types expressed among donors. However, it may also 
illustrate that T-cell responses in the periphery are fluctuating 
due to different inflammatory conditions of the hosts. In con-
ditions where ARG2 are induced in cells a subsequent activa-
tion of ARG2-specific T-cells occurs. Some healthy donors that 
did not show a reaction toward a given peptide may thus have 
a positive reaction if they were examined at other time points.
Because of the differing microenvironments that lead to 
induction of ARG1 versus ARG2, it is no surprise that different 
T-cells and different tumor types in the tumor microenviron-
ment express these two enzymes differentially. MDSCs and 
tumor-associated macrophages mainly express ARG1, whereas 
ARG2 has been described as being expressed by various solid 
tumor cells, AML blasts, and CAFs. For this reason, the com-
bination of ARG1 and ARG2 for vaccination might capture 
different immunosuppressive arginase-expressing cells in the 
tumor microenvironment and benefit more patients.
Activated M1 macrophages that propagate inflammation 
arise in response to Th1 cytokines such as IFNγ.34 Of note, 
many stroma cells are not terminally differentiated and can 
revert into immunocompetent T-cells under a pro- 
inflammatory stimulus. Activation of arginase-specific T-cells 
by a trigger such as vaccination should indeed cause Th1 
inflammation at the tumor site.22 We have reported that 
other types of anti-Tregs exist, including IDO- and PD- 
L1–specific pro-inflammatory T-cells.35–40 We have further 
reported that Th1-inflammation signals, such as IFNγ, sponta-
neously lead to the expansion of these IDO- and PD- 
L1–specific T-cells,36,41 suggesting a potential synergism of 
arginase with IDO- or PDL1-based vaccines. In this scenario, 
ARG1/ARG2 vaccination could induce Th1 inflammation at 
tumor sites, where arginase-expressing cells otherwise prevent 
lymphocyte infiltration. In turn, this effect would induce IDO 
and/or PD-L1, enabling further targeting by anti-Tregs that 
recognize epitopes derived from these targets. Thus, the com-
bination of epitopes from different anti-Treg target antigens 
could be additive in a vaccination approach.
Combination therapy with ARG2 immune-modulatory vac-
cines that activate ARG2-specific T-cells and checkpoint- 
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blocking antibodies should increase the number of patients 
able to respond to therapy compared to checkpoint blockade 
alone, which works only in inflamed tumors. Arginase- 
expressing cells prevent effector lymphocyte proliferation at 
the tumor site [8] and are an important reason for the lack of 
effect of anti-PD1 therapy in many patients with cancer. Here 
we confirmed that ARG2 is indeed expressed in poorly 
immunogenic42 and anti-PD-1–resistant43 tumor model 
Lewis lung carcinoma. We find that activation of ARG2- 
specific T-cells by vaccination significantly inhibits Lewis 
lung carcinoma tumor growth. ARG2-expression has pre-
viously been described in the LL model, and ARG2 seems to 
be expressed more in CAFs and TAMs than in cancer cells44 
underlining the immune modulatory character of the ARG2 
vaccine.
In summary, we report that ARG2-specific T-cells are 
a natural part of the immune system and can be readily 
employed to tip the balance away from immune suppression 
in cancer. Therapeutic vaccination against ARG2 should pro-
mote generation of an inflammatory tumor microenvironment 
that would favor cancer-specific immune responses against 
cancer cells. It is therefore likely that an ARG2-based vaccine 
would function synergistically with another immunotherapy, 
especially checkpoint inhibitors. The most immunogenic pep-
tide used here efficiently stimulated ARG2-specific T-cell 
responses. This function may be vital for rebalancing the 
microenvironment and should increase the effect of T-cell– 
enhancing drugs, such as checkpoint blockers, compared to 
monotherapy or current vaccines that target only cancer cells.
Methods
Patient material
PBMCs from healthy donors were isolated using density gra-
dient separation over Lymphoprep™ (Alere) and cryopreserved 
at −150°C in FBS (Life Technologies) supplemented with 10% 
DMSO. PBMCs from cancer patients with solid tumors were 
isolated from blood samples taken a minimum of four weeks 
after the termination of any anti-cancer therapy. PBMCs from 
patients with AML were isolated from blood samples taken 
from patients at different disease and treatment stages, thus 
including patients in therapy. PMBCs were maintained in X– 
vivo (BioNordika) supplemented with 5% human serum 
(Sigma Aldrich).
Cell culture
THP-1 were cultured in RPMI (Gibco) supplemented with 10% 
FBS. Set2 cells were cultured in RPMI with 20% FBS. OCI- 
AML-2 cells were cultured in Alpha-MEM (Life Technologies) 
with 10% FBS. MONO-MAC-1 cells were cultured in RPMI 
supplemented with 10% FBS, 1 mM sodium pyruvate (Life 
Technologies), 2 mM L-glutamine (Life Technologies) and 1x 
non-essential amino acids (Life Technologies). All cell lines 
were tested and confirmed negative for mycoplasma. Cells 
were passaged 2–3 times a week. Cytokine stimulation with 
IL-4 (400 U/ml), IL-13 (50 ng/ml), IFNy (100 U/ml) or 
cytokine cocktail (400 U/ml IL-4, 1000 U/ml GM-CSF and 
1000 U/ml TNFα) was done by seeding of 0.5–0.75 mio cells 
pr. ml medium supplemented with the respective cytokines 
and 48 hrs of incubation before cells were harvested for various 
experiments. All cytokines are from Trichem.
Tumor derived cell line Lewis lung carcinoma (LL/2), B16. 
F10, MC38 and GL261 were cultured in DMEM supplemented 
with penicillin, streptomycin and 10% FBS. Pan02 cells were 
cultured in RPMI supplemented with penicillin, streptomycin 
and 10% FBS while EO771 cells were cultured in DMEM 
supplemented with 20% FCS and HEPES buffer. Cells were 
passaged 2–3 times a week by detachment from the flask with 
0.25% Trypsin-EDTA (Gibco).
Peptides
The ARG2 peptide library of 34 20mer peptides was synthesized 
by PepScan and dissolved in DMSO at 10 mM for screening for 
immune responses. For remaining experiments, ARG2-1 was 
dissolved in sterile water at 2 mM. Long ARG2 peptides (A2L1, 
A2L2, A2L3) were synthesized by Schäfer and dissolved at 2 mM 
in sterile water. Peptides dissolved in sterile water was filtered 
through a 0.22 µm filter before use. Purity of the synthesized 
peptides were >90 %. For a list of all peptides, see supplementary 
table 1.
Peptide stimulation and ELISPOT assay
PBMCs from healthy donors or cancer patients were stimu-
lated with 10 µM of ARG2-derived peptides in vitro to enhance 
assay sensitivity. On day 2, IL-2 was added to a total of 120 U/ 
ml IL-2 (Novartis). After 7 days, 4–6 × 105 PBMCs were placed 
at the bottom of an ELISPOT plate pre-coated with IFNy 
capture antibody (Mabtech). PBMCs from each donor or 
patient were set up in triplicates or quadruplicates for peptide 
(5 µM ARG2-derived peptide) and control stimulations. Cells 
were incubated in ELISPOT plates in the presence of an anti-
gen for 14–16 hrs after which they were washed off and sec-
ondary biotinylated antibody (Mabtech) was added. After two 
hours of incubation the secondary antibody was washed off 
before addition of streptavidin conjugated alkaline phospha-
tase (Mabtech) for 1 hr. Next, unbound enzyme was washed off 
and the assay was developed by adding BCIP/NBT subtrate 
(Mabtech). Developed ELISPOT plates were analyzed on CTL 
Immunospot S6 Ultimate-V analyzer with ImmunoSpot soft-
ware, version 5.1. Responses are reported as the difference 
between average number of spots in well stimulated with 
ARG2-derived peptides and control wells.
ELISPOT assays with ARG2-specific T-cells (effector cells) and 
various immune or cancer cells as target cells were setup by placing 
1–5 × 104 effector cells (as indicated) and 1–2.5 × 104 targeT-cells 
(as indicated) in the bottom of an ELISPOT well. Peptide pulsing of 
targeT-cells were performed by incubation of cells with 20 µM 
peptide for 1 hr followed by two washes to remove unbound 
peptide. These cells served as positive control. Effector cells plated 
without target cells served as negative control. All conditions were 
setup in triplicates or quadruplicates.
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Intracellular cytokine staining assay
Intracellular staining of cell cultures was performed on PBMCs 
after one week of ARG2-derived peptide stimulation in vitro. For 
the assay, 9 × 105 PMBCs were re-stimulated with ARG2-derived 
peptides (or incubated with no peptide as a control) for 5 hours 
in the presence of BD GolgiPlugTM (added after the first hour of 
peptide stimulation). Stimulated cells were stained with fluores-
cently labeled antibodies for surface markers (CD3, CD4, CD8) 
and thereafter permeabilized by using Fixation/Permeabilization 
and Permeabilization Buffer (eBioscience, cat. 00–5123-43), 
according to manufacturer’s instructions. Permeabilized cells 
were then stained with fluorochrome-labeled antibodies for 
IFNγ and TNFα. Flow cytometry analysis was performed on 
a FACSCantoTM II (BD Biosciences). Antibodies used: IFNγ- 
APC, TNFα-BV421, CD4-PerCP, CD8-FITC, CD3-APC-H7, 
CD4-FITC, CD8-PerCP, and dead cells stain- FVS510 (all from 
BD Biosciences) according to manufacturer’s instructions. For 
intracellular cytokine staining to detect cytokine production of 
ARG2-specific T-cells in response to targeT-cells, 5 × 105 ARG2 
specific cells were incubated with 2.5 × 105 targeT-cells for 
5 hours with GolgiPlug™ added after the first hour.
Establishment of ARG2-specific T-cell cultures
The ARG2-specific T-cell culture was established by initial 
stimulation of PMBCs from a prostate cancer patient with 
irradiated ARG2-1 loaded autologous mature dendritic cells. 
The following day IL-12 (20 U/ml) and IL-7 (40 U/ml) was 
added. PBMCs were restimulated every 8 days with ARG2-1 
peptide loaded autologous DCs followed by addition of IL-2 
(120 U/ml) the next day. ARG2-specific T-cells were enriched 
using IFNy enrichment kit (MiltenyiBiotec) after 4 stimula-
tions. Cells were expanded and ARG2-specific T-cells were 
further enriched using CD4+ enrichment kit (MiltenyiBiotec).
Production of in-vitro transcribed mRNA
The cDNA encoding ARG2 (NM_001172.4) was synthesized 
and cloned into the HLA Class II targeting plasmid pGEM-sig- 
DC.LAMP (kindly provided by Dr. K. Thielemans, Medical 
School of the Vrije Universiteit Brussel) using BamHI restric-
tion sites. The pGEM-ARG2-DC-LAMP plasmid was linear-
ized with SpeI before serving as DNA template for in vitro 
transcription .45
Total RNA extraction
Cells were harvested, washed in PBS and pelleted by centrifuga-
tion. Cell pellets were kept on ice or frozen down at −80°C until 
RNA extraction. Total RNA was extracted using the RNAeasy 
Plus Mini Kit (Qiagen) according to manufacturer’s instruction 
with final elution in 30 µl of RNA-free water. The RNA concen-
tration was measured on the NanoDrop 2000 Spectrophotometer 
(Thermo Scientific). RNA was stored at −80°C.
RT-qPCR
Total RNA was reverse transcribed using the High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems). For 
each reaction, 1000 ng RNA was reverse transcribed. For RT- 
qPCR, the cDNA was diluted 1:5 and subjected to RT-qPCR 
analysis using the TaqMan Gene Expression Assay on the 
Roche Lightcycler 480 Instrument. RT-qPCRs were run in 
quadruplicates and data was analyzed using the dCT-method 
with normalization to expression level of the house keeping 
gene RPLPO and control sample. For low concentration sam-
ples that were not amplified, Ct was set to 40. No-reverse 
transcriptase controls (cDNA reactions setup without reverse 
transcriptase) served as controls of specific amplification. A list 
of primers used in this study is found in supplementary table 4.
Electroporation
For mRNA, DCs or cancer cells were transfected with 
ARG1-DC-LAMP mRNA, ARG2-DC-LAMP mRNA or con-
trol mRNA encoding eGFP using electroporation para-
meters as previously described. Briefly, cells were washed 
twice in Opti-MEM medium (Thermo Scientific) and 
adjusted to a final cell concentration of 9–12 × 106 cells/ 
ml. 350 µl cell suspension was preincubated on ice for 
5 minutes before addition of 10 µg mRNA. The cell suspen-
sion was then quickly transferred into a 2-mm (cancer cells) 
or 4-mm (DCs) gap electroporation cuvette and 
electroporated.45 After electroporation, cells were quickly 
transferred to a dish with pre-warmed medium and incu-
bated in humidified atmosphere with 5% CO2 before use for 
different experimental analysis. mRNA transfected cells were 
rested for 1 hr before they were setup in ELISPOT assay or 
rested overnight before set-up in intracellular cytokine 
staining assay. Electroporation efficiency was determined 
24 hours post transfection by FACS analysis of the GFP 
transfected cells.
siRNA mediated ARG2 silencing
A set of three siRNA duplexes targeting ARG2 was obtained 
from Ambion (ARG2 Silencer Select Validated siRNA, ID 
s1571, s1572, s1573). siRNAs were suspended in nuclease free 
water to 0.1 nmol stock solutions and stored at −80°C. For 
ARG2 silencing experiments, THP-1 cells were prepared for 
electroporation as described above and 10 µl of a working solu-
tion of 0.02 nmol siRNA solution was added of each of the three 
siRNA before transfection as previously described. Immediately 
after transfection, cells were transferred to pre-warmed medium 
and incubated for 1 hr. Transfected cells were then split in two, 
and to half of the cells cytokine cocktail (400 U/ml IL-4, 1000 U/ 
ml GM-CSF and 1000 U/ml TNFα) was added. Cells were 
incubated in medium or medium containing cytokine cocktail 
for 48 hrs before they were set up in intracellular cytokine 
staining assay. Cells were pelleted for RNA after 48 hrs for 
accession of knock down efficiency by RT-qPCR.
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Flow cytometric analysis of HLA-DR expression
HLA-DR expression analysis was performed on cells stimu-
lated for 48 hrs with mock (no cytokines), IFNy (100 U/ml) or 
cytokine cocktail (400 U/ml IL-4, 1000 U/ml GM-CSF and 
1000 U/ml TNFα). Briefly, cells were washed and stained 
with 7-AAD (cat: 51–68981E, BD Bioscience) and FITC- 
conjugated mouse anti-human HLA-DR, DP, DQ (cat: 
5555581, BD Bioscience) or FITC-conjugated mouse IgG1 K 
isotype ctrl (FC) (cat: 400109, BD Bioscience) for 30 minutes at 
4 °C. Excess antibody was washed off before cells were analyzed 
on FACSCanto™ II instrument. HLA-DR expression levels is 
given as the difference in MFI between MHC Class II stained 
live cells and isotype control stained live cells.
Animal experiments
Animal experiments were performed at the animal facility of 
the Department of Oncology, Herlev Hospital. Daily care and 
breeding of C57BL/6 mice was performed by animal caretakers 
of the animal facility. For the therapeutic vaccination studies, 
C57BL/6 mice were purchased from Taconic.
Tumor injections
LL2 cells (5*10^5) were resuspended in 100ul of serum free 
medium and were injected subcutaneously in the right flank of 
female C57BL/6 mice. Tumor volumes were measured by digi-
tal caliper and calculated according to the formula 
Volume = (Length x Width^2)/2. The endpoint of the tumor 
studies was a tumor reaching the threshold size of 1000 mm3 or 
due to the formation of ulcers on the tumor.
Peptide vaccination and murine ELISPOT
Murine ARG2 peptides (P1-P6) were synthesized by PepScan 
or Schäfer and dissolved in either ultrapure water or DMSO 
at 2 mM or 10 mM, respectively, depending on the reported 
solubility. Dissolved peptides were subsequently emulsified 
with Montanide adjuvant (50 αl/mouse) (Seppic Inc.) for an 
optimal dose of 100 αg total peptide given in a total volume of 
100 αl. The emulsified peptide vaccination was injected sub-
cutaneously at the base or the tail or the flank of 12–16 weeks 
old C57BL/6 mice with a 27 G needle. Control mice were 
given water and Montanide emulsification in a total volume 
of 100 αl. For therapeutic vaccine studies on tumor inoculated 
mice, vaccinations were given at day 0 and 7 after tumor 
inoculation at the flank of the tail and the left flank, respec-
tively. For epitope screening – and validation experiments, 
a single dose of vaccine was given to mice at the right flank. 
One week later, mice were sacrificed, and spleens were recov-
ered. Spleens were smashed through a 70 µM filter and red 
blood cells were lysed using Red Blood Cell Lysis Buffer 
(Qiagen). Cells were washed 4 times and counted before 
setup for murine IFNy ELISPOT assay with 8*106 cells pr. 
well.
Statistical analysis
ELISPOT responses were analyzed using distribution free 
resampling (DFR) method, described by Moodie et al.46 
Statistical analysis of ELISPOT responses was performed 
using R studio. The difference in responses (specific IFNy- 
secreting cells) toward ARG2-1 and A2L2 were compared 
with the use of Wilcoxon matched pairs signed ranked t test 
(using Prism 8) with a significance level of 0.05. Two-tailed 
Student t-test was performed to determine statistical signifi-
cance between tumor sizes at single timepoints and Two-way 
ANOVA with Bonferroni correction was used to determine 
statistical significance for entire tumor growth curves with 
comparison between multiple timepoints (using Prism 8).
Study approval
All protocols were approved by the Scientific Ethics Committee 
for the Capital Region of Denmark and conducted in accor-
dance with the provisions of the Declaration of Helsinki. 
Permission to collect samples from AML patients was granted 
from the Scientific Ethics Committee of Region Zealand. 
Written informed consent from the patients was obtained 
before study entry. All animal experiments were reviewed and 
approved by the Danish Animal Experimentation Council.
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